Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal down6.230 -0.010 (-0.160%)
Others

30/07/2021 10:53

Sino Biopharm (01177) gets drug registration certificate

[ET Net News Agency, 30 July 2021] Sino Biopharmaceutical Limited (01177) said
"Edaravone Injection" (Brand name: Fenghaiyi) (Approved specification: 20ml: 30mg), a
brain neuroprotective agent developed by the group, has obtained drug registration
certificate granted by the National Medical Products Administration of the People's
Republic of China. The product was filed as a Chemicals Category 3 drug, and is deemed to
have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.
Edaravone is a free radical scavenger, which can reduce brain oedema and tissue damage,
and effectively protect brain nerves. It can be used not only in the treatment of acute
cerebral infarction and cerebral embolism with bleeding tendency, but also in the
treatment of the rare disease amyotrophic lateral sclerosis. (RC)

Remark: Real time quote last updated: 21/09/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.